Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
- Conditions
- Cow's Milk Allergy
- Registration Number
- NCT02414243
- Lead Sponsor
- Laboratorios Ordesa
- Brief Summary
- This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged\< 12 years with documented cow's milk protein allergy (CMPA). 
- Detailed Description
- Not Provided 
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
- 
Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2): - Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR
- Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR
- Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test
 
- 
Aged ≤12 years of age at screening. 
- 
Expected consumption of a minimum of 250ml of study formula per day during the open challenge. 
- 
Written informed consent from one or both parents (depending on the local legislation) or legal representative. 
- Children who receive breastfeeding at study enrolment.
- Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema;
- Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years;
- Existing illness that could interfere with formula acceptance or identification of allergic reactions.
- Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
- Name - Time - Method - Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula - 14 days - To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study. 
- Secondary Outcome Measures
- Name - Time - Method - Cow's Milk Allergy Related Symptoms - 14 days - Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS). 
 The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA.
 If final score \<12, the symptoms are less likely related to cow's milk. Look for other causes.
Trial Locations
- Locations (1)
- Ospedale Pediatrico Bambino Gesù 🇮🇹- Rome, Italy Ospedale Pediatrico Bambino Gesù🇮🇹Rome, Italy
